Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC. Wednesday, the FDA approved Merck ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $115.25 which represents a slight increase of $0.54 or 0.47% from the prior close of $114.71. The stock opened at $114.47 and touched ...

Merck (MRK) closed at $115.86 in the latest trading session, marking a +0.53% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.54% for the day.

Thank you for attending our Global Healthcare Conference. Today, I have the pleasure to host Joe Romanelli, President of Human Health International; and Peter Dannenbaum, Head of Investor Relations.

**NM signifies a non meaningful value. A dash signifies the data is not available.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other blue chip stocks. While economic data may be scarce, every data point gives a new angle ...